Notice of AGM & availability of Annual Report

Futura Medical PLC

04 June 2026

 

4 June 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Notice of AGM & Availability of Annual Report

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces its Annual General Meeting ("AGM") will be held at 10:00am on Monday, 29 June 2026 at the offices of Panmure Liberum, Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.

If you wish to attend the meeting in person, please register your interest at [e-mail].

Shareholders are asked to cast their vote as follows: (1) casting your proxy vote online via the Investor Centre app or by accessing the web browser at https://uk.investorcentre.mpms.mufg.com/ and following the instructions; or (2) in the case of CREST members, by utilising the CREST electronic proxy appointment service; or (3) if you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform; or (4) requesting a hard copy form of proxy directly from the Registrars, MUFG Corporate Markets. For further information, please refer to the notes to the Notice of Annual General Meeting. If you choose to attend the Annual General Meeting in person instead of appointing the Chairman of the meeting as proxy, you will still be able to vote in person at the Annual General Meeting.

If you are not attending the Annual General Meeting in person, your proxy vote will need to be logged by 10:00am on Thursday, 25 June 2026, as no online voting will take place in-real time during the meeting itself.

Annual Report

Futura's annual report and accounts for the year ended 31 December 2025 (the "Annual Report") is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available on the Company's website www.futuramedical.com, along with the Notice of AGM.

Contacts:

Futura Medical plc	Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO	[e-mail] [phone] www.futuramedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	[phone]
Turner Pope Investments (TPI) Ltd - Broker	Guy McDougall, Andrew Thacker	[phone]
Alma Strategic Communications	Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters	[phone] [e-mail]

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon^® and development projects WSD4000 and Eroxon^® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.

Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve months period, with only one in four women seeking professional help and remaining chronically underserved.

Eroxon^®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon^®, across major consumer markets.

WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.

 

END